Roche mulls costs and staff cuts by year end
This article was originally published in Scrip
Roche is mulling over plans to slash its operating costs to cope with "mounting pressures to curb healthcare costs" and to deal with a spate of recent setbacks in its late-stage programmes. It said it would review and analyse its organisation's structures and processes and announce what measures will be taken before the end of the year.
You may also be interested in...
Roche's CEO Severin Schwan says corporate nurturing and support consistently given by the pharma's founding families have helped him take the long view, even in difficult times.
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.